What type of study is this?

This is a Experimental Study study.

October 10, 2025

Multi-omics analysis reveals CLEC2A is a leukemia-restricted CART target in KMT2A-rearranged Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Authors

Multi-omics approach reveals CLEC2A as a novel target for CART cell therapy in acute myeloid leukemia, suggesting improved outcomes.

CLEC2A-targeting CART cells enhance survival in AML models, indicating a promising therapeutic option.
Analysis showed CLEC2A is expressed in high-risk KMT2A-rearranged AML but not in normal cells, highlighting its potential as a target.
The adoptive therapy approach may offer a safer alternative to traditional methods, minimizing myeloablation risk and maximizing efficacy.
First-in-class human CLEC2A binders were developed, paving the way for advancing leukemia-targeting therapies in clinical settings.

Kirkey et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark